Blog post: ARC attends datasharing meeting
Data sharing. It is an important topic and there is a real need for it in our community. Data sharing encourages more connection and collaboration among researchers, which can result in important new findings within the field. (more…)
ARC sponsored Satellite Symposium at HFSA
For the third year running, ARC is supporting a CME Satellite Symposium at the Heart Failure Society of America (HFSA) conference. "Avoiding the pitfalls of diagnosing and treating cardiac ATTR amyloidosis" will be held on Sunday evening, September 15, at...
Publication of cardiac ATTR amyloidosis diagnosis guidelines
ARC-supported consensus best practices guidelines for the diagnosis of cardiac ATTR amyloidosis published in the journal of the American Heart Association, Circulation:Heart Failure. (more…)
Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) approved by FDA
This represents the first FDA approved treatment in ATTR-CM for both the wild-type and hereditary forms of ATTR amyloidosis. (more…)
Patient Perspectives from the FDA Public Meeting: the Impact of Rare Diseases
I recently had the opportunity to attend this public meeting at the FDA to discuss the Patient Perspectives on the Impact of Rare Diseases. This meeting was held as opportunity to bring the voices of patients and caregivers to the...